

OTT Operating Memo No. 96-1  
January 9, 1996  
Attachment E

Sample Letter

DATE

Dr. Linda L. Gardner  
Director, Administrative Operations  
79 Alexander Drive  
Building 4401, Suite 300  
P.O. Box 12053  
Research Triangle Park, NC 27709

Subject: SRC Contract No. [SRC Project No.] [PI Name]

Dear Dr. Gardner:

Pursuant to Appendix I, paragraph 13.2(c), of the subject contract, the University reserves the right to assert against SRC and/or its Members the background rights as identified in the enclosure, hereto. In addition, the University further reserves the right to assert against SRC and/or its Members all background rights arising out of the national laboratories managed by the University, and all background rights that have not yet been disclosed to the University.

SRC execution of the subject contract will be considered SRC mutual agreement to this reservation of the University's right to assert background rights pursuant to Appendix I, paragraph 13.2(c). If SRC and/or its Members wish to seek a license to any such background rights, SRC should contact the appropriate University licensing office to assess the availability of such rights for licensing and the related licensing terms.

Sincerely,

Campus Contract and Grant  
Officer

Enclosure

cc: OTT Campus Liaison Manager (w/o Enclosure)

PTS Report 851  
Run 01/08/96

\*\*\* CONFIDENTIAL REPORT \*\*\*

Office of Technology Transfer

Page OTT- 29

Technologies For Which The University of California  
Reserves Assertion Rights Under The UC/SRC Agreement

UC Case No.	Lead Inventor's Campus	Invention Short Title	Patent No. (If Any)
OTT-92-186-1	DA	NOVEL PHOTSENSITIZERS	
OTT-92-188-1	SF	CHLAMYDIA	
OTT-92-191-1	IR	QM MULTIGENE FAMILY	
OTT-92-196-1	SD	SYNTH OF NOVEL OLIGOSACCHARIDE	
OTT-92-197-1	SD	CALICHEAMICIN GAMMA 1 MIMICS	
OTT-92-197-2	SD	CALICHEAMICIN GAMMA 1 MIMICS	
OTT-92-198-1	SD	ANTITUMOR AGENTS - SELECTIVE	
OTT-92-199-1	SD	10 MEMBERED RING ENEDIYENES	5,183,942
OTT-92-201-1	SF	LIPID BARRIER FORMULAE/THERAPY	
OTT-92-202-1	NUC	DTRP-6-LHRH TO ALTER BEHAVIOR	
OTT-92-206-1	SD	RHEUMATISM PROTEIN ASSAY	
OTT-92-206-2	SD	RHEUMATISM PROTEIN ASSAY	
OTT-92-207-1	SD	PLANT RESISTANCE TO METAL TOX.	
OTT-92-208-1	SD	EXTENDING CIRCULATORY LIFETIME	
OTT-92-209-1	RV	INSECTICIDAL OILS	
OTT-92-211-1	SF	PANCREATIC BETA CELL LINE	
OTT-92-214-1	SD	PROCESS FOR ANTIVIRAL ACTIVITY	
OTT-92-221-1	SF	MRI MAGNETIC SHIMMING	
OTT-92-229-1	SD	INTEGRIN MAB-12F1	
OTT-92-230-1	SD	INTEGRIN MAB 4F10	
OTT-92-232-2	SF	ANTI-HD ACTIVITY	
OTT-92-232-3	SF	ANTI-HD ACTIVITY	
OTT-92-239-1	DA	AIRBORNE PARTICLES SAMPLING	5,412,975
OTT-92-240-1	SF	METHOD OF MEDICATION INTO CELLS	
OTT-92-241-1	SF	URINE COLLECTING DEVICE WOMEN	4,846,817
OTT-92-245-1	SB	MAGNETIC FORCE CONTROL. PROBE	
OTT-92-247-2	DA	CONTROL RELEASE BIOMATERIAL	
OTT-92-248-1	IR	TINY KING MICROPROCESSOR	
OTT-92-253-2	LA	ASSAY FOR SUTTON ALLERGY	
OTT-92-254-1	SD	RESPIRATOR VENTILATOR'S BUFFER	
OTT-92-256-2	SF	ANTI-MALARIAL COMPOUND	
OTT-92-256-3	SF	ANTI-MALARIAL COMPOUND	
OTT-92-257-1	LLL	TITANIUM LIGHTWEIGHT CERMETS	
OTT-92-258-1	BK	MIXED-WASTE SPILL REMEDIATION	
OTT-92-259-1	SB	SOLAR CELLS FM. COND. POLYMERS	5,331,183
OTT-92-259-2	SB	SOLAR CELLS FM. COND. POLYMERS	5,454,880
OTT-92-260-1	SF	PHOSPHOLIPASE A2 ENZYME ASSAY	5,464,754
OTT-92-261-1	SF	PAN-SPECIES INTEGRIN ANTIBODY	
OTT-92-263-2	SF	PROTEIN EXPRESSION IN HALOBACT	
OTT-92-267-1	IR	ENDOSCOPIC PDT LIGHT DIFFUSER	
OTT-92-269-1	SD	SELF-TUNED FABRY-PEROT OPT MOD	
OTT-92-271-2	DA	LOW TEMP DIRECT CHIP BONDING	
OTT-92-272-1	BK	FAST ACTING BACULOVIRUS	
OTT-92-275-1	DA	MICROMACHINED ACCELEROMETER	
OTT-92-276-1	RV	INHIBITORY METABOLITE OF VITD3	
OTT-92-276-2	RV	INHIBITORY METABOLITE OF VITD3	
OTT-92-281-1	DA	MONOCLONAL TO BETA INTEGRIN	
OTT-92-283-1	SD	RMET G-LYASE TO TREAT CANCER	
OTT-92-285-1	SF	UTERINE CONTRACTION MONITOR	5,373,852
OTT-92-286-1	SD	FOS ASSAYS IN NEURONAL CELLS	
OTT-92-289-2	SF	DRUG TARGETING TO PLATELETS	